FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048683263> ?p ?o ?g. }

• W3048683263 endingPage "1761" @default.
• W3048683263 startingPage "1751" @default.
• W3048683263 abstract "Background: Many patients with Parkinson’s disease (PD) experience depression. Objective: Evaluate pimavanserin treatment for depression in patients with PD. Methods: Pimavanserin was administered as monotherapy or adjunctive therapy to a selective serotonin reuptake inhibitor or serotonin/noradrenaline reuptake inhibitor in this 8-week, single-arm, open-label phase 2 study (NCT03482882). The primary endpoint was change from baseline to week 8 in Hamilton Depression Scale–17-item version (HAMD-17) score. Safety, including collection of adverse events and the Mini-Mental State Examination (MMSE) and Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale Part III (MDS-UPDRS III) scores, was assessed in patients who received ≥1 pimavanserin dose. Results: Efficacy was evaluated in 45 patients (21 monotherapy, 24 adjunctive therapy). Mean (SE) baseline HAMD-17 was 19.2 (3.1). Change from baseline to week 8 (least squares [LS] mean [SE]) in the HAMD-17 was –10.8 (0.63) (95% CI, –12.0 to –9.5; p < 0.0001) with significant improvement seen at week 2 (p < 0.0001) and for both monotherapy (week 8, –11.2 [0.99]) and adjunctive therapy (week 8,–10.2 [0.78]). Most patients (60.0%) had ≥50% improvement at week 8, and 44.4% of patients reached remission (HAMD-17 score ≤7). Twenty-one of 47 patients experienced 42 treatment-emergent adverse events; the most common by system organ class were gastrointestinal (n = 7; 14.9%) and psychiatric (n = 7; 14.9%). No negative effects were observed on MMSE or MDS-UPDRS Part III. Conclusion: In this 8-week, single-arm, open-label study, pimavanserin as monotherapy or adjunctive therapy was well tolerated and associated with early and sustained improvement of depressive symptoms in patients with PD." @default.
• W3048683263 created "2020-08-18" @default.
• W3048683263 creator A5000558523 @default.
• W3048683263 creator A5006733714 @default.
• W3048683263 creator A5022429461 @default.
• W3048683263 creator A5031328587 @default.
• W3048683263 creator A5031935755 @default.
• W3048683263 creator A5067365646 @default.
• W3048683263 creator A5072536531 @default.
• W3048683263 creator A5080882152 @default.
• W3048683263 creator A5090177182 @default.
• W3048683263 date "2020-10-27" @default.
• W3048683263 modified "2023-09-29" @default.
• W3048683263 title "An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson’s Disease and Depression" @default.
• W3048683263 cites W132813541 @default.
• W3048683263 cites W1847168837 @default.
• W3048683263 cites W1940288196 @default.
• W3048683263 cites W1966424565 @default.
• W3048683263 cites W1967630951 @default.
• W3048683263 cites W1968565337 @default.
• W3048683263 cites W1975831734 @default.
• W3048683263 cites W1990166011 @default.
• W3048683263 cites W1999702935 @default.
• W3048683263 cites W2042158944 @default.
• W3048683263 cites W2048957687 @default.
• W3048683263 cites W2063956606 @default.
• W3048683263 cites W2065369785 @default.
• W3048683263 cites W2070828096 @default.
• W3048683263 cites W2074828631 @default.
• W3048683263 cites W2075843476 @default.
• W3048683263 cites W2084315798 @default.
• W3048683263 cites W2107881620 @default.
• W3048683263 cites W2114242191 @default.
• W3048683263 cites W2114613490 @default.
• W3048683263 cites W2141809037 @default.
• W3048683263 cites W2148083007 @default.
• W3048683263 cites W2152289942 @default.
• W3048683263 cites W2208668986 @default.
• W3048683263 cites W2519531315 @default.
• W3048683263 cites W2745470440 @default.
• W3048683263 cites W2888130307 @default.
• W3048683263 cites W2952350023 @default.
• W3048683263 cites W2969278470 @default.
• W3048683263 cites W2975176952 @default.
• W3048683263 doi "https://doi.org/10.3233/jpd-202058" @default.
• W3048683263 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7683094" @default.
• W3048683263 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32804101" @default.
• W3048683263 hasPublicationYear "2020" @default.
• W3048683263 type Work @default.
• W3048683263 sameAs 3048683263 @default.
• W3048683263 citedByCount "8" @default.
• W3048683263 countsByYear W30486832632022 @default.
• W3048683263 countsByYear W30486832632023 @default.
• W3048683263 crossrefType "journal-article" @default.
• W3048683263 hasAuthorship W3048683263A5000558523 @default.
• W3048683263 hasAuthorship W3048683263A5006733714 @default.
• W3048683263 hasAuthorship W3048683263A5022429461 @default.
• W3048683263 hasAuthorship W3048683263A5031328587 @default.
• W3048683263 hasAuthorship W3048683263A5031935755 @default.
• W3048683263 hasAuthorship W3048683263A5067365646 @default.
• W3048683263 hasAuthorship W3048683263A5072536531 @default.
• W3048683263 hasAuthorship W3048683263A5080882152 @default.
• W3048683263 hasAuthorship W3048683263A5090177182 @default.
• W3048683263 hasBestOaLocation W30486832631 @default.
• W3048683263 hasConcept C126322002 @default.
• W3048683263 hasConcept C138496976 @default.
• W3048683263 hasConcept C139719470 @default.
• W3048683263 hasConcept C15744967 @default.
• W3048683263 hasConcept C162324750 @default.
• W3048683263 hasConcept C170493617 @default.
• W3048683263 hasConcept C197934379 @default.
• W3048683263 hasConcept C203092338 @default.
• W3048683263 hasConcept C2775864247 @default.
• W3048683263 hasConcept C2776867660 @default.
• W3048683263 hasConcept C2777198177 @default.
• W3048683263 hasConcept C2779134260 @default.
• W3048683263 hasConcept C2779144063 @default.
• W3048683263 hasConcept C2779734285 @default.
• W3048683263 hasConcept C2780051608 @default.
• W3048683263 hasConcept C2780092697 @default.
• W3048683263 hasConcept C3018023364 @default.
• W3048683263 hasConcept C3018162438 @default.
• W3048683263 hasConcept C31487548 @default.
• W3048683263 hasConcept C535046627 @default.
• W3048683263 hasConcept C71924100 @default.
• W3048683263 hasConcept C83849319 @default.
• W3048683263 hasConceptScore W3048683263C126322002 @default.
• W3048683263 hasConceptScore W3048683263C138496976 @default.
• W3048683263 hasConceptScore W3048683263C139719470 @default.
• W3048683263 hasConceptScore W3048683263C15744967 @default.
• W3048683263 hasConceptScore W3048683263C162324750 @default.
• W3048683263 hasConceptScore W3048683263C170493617 @default.
• W3048683263 hasConceptScore W3048683263C197934379 @default.
• W3048683263 hasConceptScore W3048683263C203092338 @default.
• W3048683263 hasConceptScore W3048683263C2775864247 @default.
• W3048683263 hasConceptScore W3048683263C2776867660 @default.
• W3048683263 hasConceptScore W3048683263C2777198177 @default.
• W3048683263 hasConceptScore W3048683263C2779134260 @default.

• next